The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
In Singapore, a modern manufacturing facility is to be built by Chinese contract research, development and manufacturing organization (CRDMO) WuXi Biologics. 21 March 2024
Privately-held Californian firm Parvus Therapeutics has entered into an exclusive worldwide license collaboration and option agreement with US pharma major AbbVie. 21 March 2024
Japanese drugmaker Chugai Pharmaceuticals today announced mixed results from the Phase III LUMINESCE study of Enspryng (satralizumab [genetical recombination]), created by Chugai, as an investigational treatment for generalized myasthenia gravis (gMG). 21 March 2024
Another start-up has launched in the bustling biotech hub around Boston, USA, with $150 million in financing from investors including Novo Holdings. 21 March 2024
Angelini Ventures has announced its participation in an extension of the Series C financing round for Swiss immuno-oncology firm Nouscom. 21 March 2024
Since Swiss pharma giant Roche’s Zelboraf (vemurafenib) gained US Food and drug Administration (FDA) approval in 2011, significant strides have been made in BRAF-targeted cancer therapies, underscoring the significance of combating BRAF mutations in melanoma. 21 March 2024
German pharma and life sciences major Merck KGaA today revealed it plans to invests more than 300 million euros ($32.7 million) into a new Bioprocessing Production Center in Daejeon, South Korea. 20 March 2024
Germany’s BioNTech has announced the appointment of Annemarie Hanekamp as the company’s new chief commercial officer, succeeding Sean Marett. 20 March 2024
German BioNTech stock fell nearly 9% to 85.72 euros in early trading today, as the company – which came into the limelight with the super successful COVID-19 vaccine Comirnaty partnered with Pfizer – as it posted financial results that disappointed. 20 March 2024
A statement from the Centers for Disease Control and Prevention (CDC) in the USA raises concerns about the spread of measles, a public health issue which has affected multiple countries in recent years. 20 March 2024
Italfarmaco has announced that results from its pivotal Phase III EPIDYS trial with givinostat in ambulant boys aged six years and older with Duchenne muscular dystrophy (DMD) have been published in The Lancet Neurology. 20 March 2024
Following the US Food and Drug Administration approval last Friday of its Lenmeldy (atidarsagene autotemcel), Orchard Therapeutics today announced launch plans for the gene therapy. 20 March 2024
Capping a series of investments designed to increase its manufacturing footprint, Novo Nordisk has said it will spend around $550 million to up output in China. 20 March 2024
The US Food and Drug Administration (FDA) has granted accelerated approved the supplemental new drug application (sNDA) for Iclusig (ponatinib). 20 March 2024
Members of the European Parliament’s health committee (ENVI) yesterday adopted a compromise position on the EU Pharmaceutical legislation review (comprising of a new Pharmaceutical Directive and Regulation). 20 March 2024